Daewoong Pharma (069620) - Total Liabilities

Latest as of September 2025: ₩1.26 Trillion KRW ≈ $851.43 Million USD

Based on the latest financial reports, Daewoong Pharma (069620) has total liabilities worth ₩1.26 Trillion KRW (≈ $851.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Daewoong Pharma - Total Liabilities Trend (2007–2024)

This chart illustrates how Daewoong Pharma's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Daewoong Pharma to evaluate short-term liquidity relative to the company's equity base.

Daewoong Pharma Competitors by Total Liabilities

The table below lists competitors of Daewoong Pharma ranked by their total liabilities.

Company	Country	Total Liabilities
China Reinsurance (Group) Corporation F:C53	Germany	€408.45 Billion
National Presto Industries Inc NYSE:NPK	USA	$109.52 Million
Guilin Seamild Foods Co Ltd SHE:002956	China	CN¥641.82 Million
LightPath Technologies Inc NASDAQ:LPTH	USA	$31.38 Million
Shanghai Anoky Group SHE:300067	China	CN¥1.03 Billion
LegalZoom.com Inc NASDAQ:LZ	USA	$344.95 Million
Winall Hi tech Seed SHE:300087	China	CN¥4.34 Billion
Voltalia SA PA:VLTSA	France	€3.13 Billion

Liability Composition Analysis (2007–2024)

This chart breaks down Daewoong Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Daewoong Pharma market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.15	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.43	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.56	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Daewoong Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Daewoong Pharma (2007–2024)

The table below shows the annual total liabilities of Daewoong Pharma from 2007 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩1.05 Trillion ≈ $711.56 Million	+37.65%
2023-12-31	₩762.77 Billion ≈ $516.92 Million	-7.22%
2022-12-31	₩822.12 Billion ≈ $557.14 Million	+15.34%
2021-12-31	₩712.77 Billion ≈ $483.04 Million	+6.12%
2020-12-31	₩671.66 Billion ≈ $455.17 Million	+10.15%
2019-12-31	₩609.75 Billion ≈ $413.22 Million	+1.62%
2018-12-31	₩600.04 Billion ≈ $406.64 Million	+3.10%
2017-12-31	₩581.99 Billion ≈ $394.40 Million	+7.75%
2016-12-31	₩540.15 Billion ≈ $366.05 Million	+48.28%
2015-12-31	₩364.29 Billion ≈ $246.87 Million	+52.58%
2014-12-31	₩238.76 Billion ≈ $161.80 Million	+69.27%
2013-12-31	₩141.05 Billion ≈ $95.59 Million	+47.30%
2012-12-31	₩95.76 Billion ≈ $64.89 Million	-29.61%
2011-12-31	₩136.04 Billion ≈ $92.20 Million	-34.40%
2008-12-31	₩207.39 Billion ≈ $140.55 Million	+68.28%
2007-12-31	₩123.24 Billion ≈ $83.52 Million	--

About Daewoong Pharma

KO:069620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$944.29 Million

₩1.39 Trillion KRW

Market Cap Rank

#9314 Global

#251 in Korea

Share Price

₩121100.00

Change (1 day)

-1.94%

52-Week Range

₩118300.00 - ₩194000.00

All Time High

₩272265.92